-
Mashup Score: 3Testosterone Recovery for Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer: Results From the Phase 3 HERO Study. - 2 year(s) ago
ASCO GU 2022 HERO study men who did not continue androgen deprivation therapy on an ongoing basis, HERO study oral GnRH receptor antagonist relugolix, relugolix had faster and more complete recovery of testosterone to normal levels after treatment discontinuation as compared with leuprolide in phase 3 HERO study
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
ASCO GU 2022 secondary analysis of the HERO trial of relugolix focused on the effect of concomitant cardiovascular (CV) therapies on efficacy and safety measures in this trial.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix vs leuprolide in men with adv #ProstateCancer: Subgroup analysis from the phase 3 #HERO study. Presented by Neal Shore, MD, FACS @AtlanticUrology. #GU22 @WallisCJD > https://t.co/1Y8AltdMOD @ASCO https://t.co/DvAGWVgw13
-
-
Mashup Score: 4
I believe the Covid-19 vaccine and booster saved my kids from losing their mother. Covid has stripped me of my one strategy for living: pushing through everything. But what it hasn’t done is killed me. And that’s everything, because I’m a mom.
Source: ForbesCategories: Latest Headlines, PediatricsTweet-
In what is the most personal article I've ever written, I explore for Forbes the healthcare #hero complex, #presenteeism, and why I believe the COVID vaccine #BoosterDose saved my kids from losing their mother. #healthcare #motherhood https://t.co/sZbQHHGe0q
-
-
Mashup Score: 0Impact of Age on Efficacy and Safety of Relugolix in the Phase 3 HERO Study Versus Leuprolide in Men with Advanced Prostate Cancer - Fred Saad - 2 year(s) ago
The HERO study was a randomized, open-label, parallel-group study evaluating relugolix in men with advanced prostate cancer. Overall, 934 men with advanced prostate cancer underwent 2:1 randomization to receive relugolix 120 mg orally once daily after a single loading dose of 360 mg or leuprolide 3-month injections for 48 weeks. Subgroups analyzed by age were <65 years or ≥65 years and ≤75...
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Impact of age on efficacy and safety of relugolix in the phase 3 #HERO study vs leuprolide in men with advanced #ProstateCancer. Fred Saad, MD, FRCS @chumontreal joins @charlesryanmd @UMNCancer highlighting a subset analysis on UroToday > https://t.co/fBwpTy5tpQ https://t.co/ZZG3RUYv9n
-
-
Mashup Score: 0Notable Heroes in Health Care: Jesse Ehrenfeld - 2 year(s) ago
As director of Advancing a Healthier Wisconsin, an endowment set up by the Medical College of Wisconsin, Dr. Jesse Ehrenfeld directed nearly $5 million in
Categories: Healthcare Professionals, Latest HeadlinesTweet-
So incredibly honored to be named a @BizTimesMedia "Notable #Hero in #Healthcare" https://t.co/ekJfYePOCh @MedicalCollege @ahwendowment @AmerMedicalAssn
-
-
Mashup Score: 1
Alicia Morgans, MD, MPH, and Michael Cookson, MD, MMHC, FACS, discuss age subgroups in the HERO trial, evaluating differences in castration rates between patients of different ages from the HERO Study. The HERO trial evaluated relugolix compared to standard androgen deprivation therapy with leuprolide. Dr. Cookson discusses how they performed the analysis. The evaluation demonstrated that…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Impact of age on castration rates from the #HERO study. @michaelcookso18 @OUUrology and @CaPsurvivorship @DanaFarber discuss age subgroups in the HERO trial, evaluating differences in castration rates between patients of different ages. #WatchNow > https://t.co/vt4R25QF6h https://t.co/wFGRT5oz8t
-
-
Mashup Score: 3
Joining Alicia Morgans is joined by Bertrand Tombal who is highlighting two subgroup analyses from the phase III HERO trial reported at the 2021 European Society of Medical Oncology meeting. They discuss a subgroup analysis of the phase 3 HERO study assessing the efficacy and safety of relugolix versus leuprolide among men with advanced prostate cancer as well as a subgroup analysis assessing…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Relugolix in the phase 3 #HERO study in men with #mHSPC. @BertrandTOMBAL @UCLouvain_be joins @CaPsurvivorship @DanaFarber highlighting two subgroup analyses from the #HERO trial reported at #ESMO21. #WatchNow > https://t.co/quN7OpvAtL @myESMO https://t.co/DkhuwlzDBi
-
-
Mashup Score: 0
Neeraj Agarwal, MD joins Petros Grivas, MD, PhD, sharing his clinical perspective on using relugolix in patients with advanced prostate cancer, and how this new oral treatment option fits into the prostate cancer treatment algorithm. The phase 3 HERO trial looked at patients with advanced prostate cancer, locally advanced prostate cancer, as well as metastatic prostate cancer, and patients were…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Relugolix in the Treatment of Advanced #ProstateCancer. @neerajaiims @huntsmancancer joins @PGrivasMDPhD @UW sharing his clinical perspective on the use of #relugolix in patients with advanced PCa. #WatchNow on UroToday > https://t.co/A7COjiQXK7 @Myovant #HERO @SeattleCCA https://t.co/13EXAsi4F9
-
-
Mashup Score: 0Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer - Daniel J. George - 2 year(s) ago
Daniel George, MD, and Neal Shore, MD, FACS, co-investigators of the Phase III HERO Trial join Alicia Morgans, MD, MPH recapping the 2021 GU ASCO analysis that Daniel George presented on the efficacy and safety of relugolix vs leuprolide in men with advanced prostate cancer. This was a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Impact of concomitant #ProstateCancer therapy of relugolix in men with advanced prostate cancer. @Daniel_J_George @DukeCancer and Neal Shore, MD, FACS @AtlanticUrology join @CaPsurvivorship @DanaFarber to discuss a subgroup analysis of the #HERO Study > https://t.co/M0lR7JdsFJ https://t.co/qMCRTHn6EQ
-
-
Mashup Score: 2Impact of Age on Efficacy and Safety of Relugolix in the Phase 3 HERO Study Versus Leuprolide in Men with Advanced Prostate Cancer - Fred Saad - 2 year(s) ago
The HERO study was a randomized, open-label, parallel-group study evaluating relugolix in men with advanced prostate cancer. Overall, 934 men with advanced prostate cancer underwent 2:1 randomization to receive relugolix 120 mg orally once daily after a single loading dose of 360 mg or leuprolide 3-month injections for 48 weeks. Subgroups analyzed by age were <65 years or ≥65 years and ≤75...
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Impact of age on efficacy and safety of relugolix in the phase 3 #HERO study vs leuprolide in men with advanced #ProstateCancer. Fred Saad, MD, FRCS @chumontreal joins @charlesryanmd @UMNCancer highlighting a subset analysis on UroToday > https://t.co/fBwpTy5tpQ https://t.co/bFJPNSvfuv
-
Testosterone recovery for relugolix vs leuprolide in men with advanced #ProstateCancer: Results from the phase 3 #HERO study. Presented by @RTutrone @ChesUrology. #GU22 written coverage by @WallisCJD @UofT on UroToday > https://t.co/28AUII1QET @ASCO https://t.co/9P05q8H8zD